Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab

Journal of Clinical Oncology

Volumn 27, Issue 4, 2009, Pages 605-611

  Yeo, Winnie ^a   Chan, Tung C ^a   Leung, Nancy W Y ^a   Lam, Wai Y ^a   Mo, Frankie K F ^a   Miu, Ting Chu ^a   Chan, Henry L Y ^a   Hui, Edwin P ^a   Lei, Kenny I K ^a   Mok, Tony S K ^a   Chan, Paul K S ^a  

^a ALICE HO MIU LING NETHERSOLE HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIINFECTIVE AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CANCER CHEMOTHERAPY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; HEPATITIS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LARGE CELL LYMPHOMA; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; SIDE EFFECT; VIRUS REACTIVATION;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PREDNISOLONE; VINCRISTINE; VIRUS ACTIVATION;

EID: 59149085061     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.18.0182     Document Type: Article

References (39)

1. Ganem D, Prince AM: Hepatitis B virus infection: Natural history and clinical consequences. N Engl J Med 350:1118-1129, 2004
2. Lok AS, McMahon BJ: Chronic hepatitis B. Hepatology 45:507-539, 2007
3. Lok ASF, Lai CL, Wu PC: Hepatitis B virus infection in Chinese families in Hong Kong. Am J Epidemiol 126:492-499, 1987
4. Rehermann B, Ferrari C, Pasquinelli C, et al: The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 2:1104-1108, 1996
5. Yuki N, Nagaoka T, Yamashiro M, et al: Longterm histologic and virologic outcomes of acute self-limited hepatitis B. Hepatology 37:1172-1179, 2003
6. Yeo W, Johnson PJ: Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 43:209-220, 2006
7. Xunrong L, Yan AW, Liang R, et al: Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy: Pathogenesis and management. Rev Med Virol 11:287-299, 2001
8. Kitano K, Kobayashi H, Hanamura M, et al: Fulminant hepatitis after allogenic bone marrow transplantation caused by reactivation of hepatitis B virus with gene mutations in the core promotor region. Eur J Haematol 77:255-258, 2006
9. Coiffier B, Lepage E, Briere J, et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242, 2002
10. Pfreundschuh M, Trümper L, Osterborg A, et al: CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7:379-391, 2006
11. Habermann TM, Weller EA, Morrison VA, et al: Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 24:3121-3127, 2006
12. Dai MS, Chao TY, Kao WY, et al: Delayed hepatitis B virus reactivation after cessation of pre-emptive lamivudine in lymphoma patients treated with rituximab plus CHOP. Ann Hematol 83:769-774, 2004
13. Tsutsumi Y, Tanaka J, Kawamura T, et al: Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma. Ann Hematol 83:58-60, 2004
14. Dervite I, Hober D, Morel P: Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 344:68-69, 2001
15. Westhoff TH, Jochimsen F, Schmittel A, et al: Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood 102:1930, 2003
16. Loeb KR, Jerome KR, Goddard J, et al: High-throughput quantitative analysis of hepatitis B virus DNA in serum using the TaqMan fluorogenic detection system. Hepatology 32:626-629, 2000
17. Cook L, Ng KW, Bagabag A, et al: Use of the MagNA pure LC automated nucleic acid extraction system followed by real-time reverse transcription-PCR for ultrasensitive quantitation of hepatitis C virus RNA. J Clin Microbiol 42:4130-4136, 2004
18. Yeo W, Chan PKS, Ho WM, et al: Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 22:927-934, 2004
19. an der Kolk LE, Baars JW, Prins MH, et al: Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood 100:2257-2259, 2002
20. Osterborg A, Dyer MJ, Bunjes D, et al: Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia: European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol 15:1567-1574, 1997
21. Lazdina U, Alheim M, Nyström J, et al: Priming of cytotoxic T cell responses to exogenous hepatitis B virus core antigen is B cell dependent. J Gen Virol 84:139-146, 2003
22. Crowley B, Woodcock B: Red cell aplasia due to parvovirus b19 in a patient treated with alemtuzumab. Br J Haematol 119:279-280, 2002
23. Suzan F, Ammor M, Ribrag V: Fatal reactivation of cytomegalovirus infection after use of rituximab for a post-transplantation lymphoproliferative disorder. N Engl J Med 345:1000, 2001
24. Sharma VR, Fleming DR, Slone SP: Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab. Blood 96:1184-1186, 2000
25. Liaw YF, Leung N, Guan R, et al: Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2005 update. Liver Int 25:472-489, 2005
26. Sarrecchia C, Cappelli A, Aiello P: HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb. J Infect Chemother 11:189-191, 2005
27. Law JK, Ho JK, Hoskins PJ, et al: Fatal hepatitis B virus reactivation post-chemotherapy in a hepatitis B core antibody-positive patient: Potential implications for future prophylaxis recommendation. Leuk Lymphoma 46:1085-1089, 2005
28. Niscola P, Del Principe MI, Maurillo L, et al: Fulminant B hepatitis in a surface antigen-negative patient with B-cell chronic lymphocytic leukaemia after rituximab therapy. Leukemia 19:1840-1841, 2005
29. Sera T, Hiasa Y, Michitaka K, et al: Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab. Intern Med 45:721-724, 2006
30. Ozgönenel B, Moonka D, Savaşan S: Fulminant hepatitis B following rituximab therapy in a patient with Evans syndrome and large B-cell lymphoma. Am J Hematol 81:302, 2006
31. Yamagata M, Murohisa T, Tsuchida K, et al: Fulminant B hepatitis in a surface antigen and hepatitis B DNA-negative patient with diffuse large B-cell lymphoma after CHOP chemotherapy plus rituximab. Leuk Lymphoma 48:431-433, 2007
32. Uemoto S, Sugiyama K, Marusawa H, et al: Transmission of hepatitis B virus from hepatitis B core antibody-positive donors in living related liver transplants. Transplantation 65:494-499, 1998
33. Roque-Afonso AM, Feray C, Samuel D, et al: Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBc positive donors. Gut 50:95-99, 2002
34. Lau GKK, Lee CK, Liang R: Hepatitis B virus infection and allogeneic bone marrow transplantation. Crit Rev Oncol Hematol 31:71-76, 1999
35. Yeo W, Chan PKS, Zhong S, et al: Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: A prospective study of 626 patients with identification of risk factors. J Med Virol 62:299-307, 2000
36. Lok ASF, Liang RHS, Chiu EKW, et al: Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy: Report of a prospective study. Gastroenterology 100:182-188, 1991
37. Yeo W, Zee B, Zhong S, et al: Comprehensive analysis of risk factors associating with hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 90:1306-1311, 2004
38. Yeo W, Chan PKS, Chan HLY, et al: Hepatitis B virus reactivation during cytotoxic chemotherapy: Enhanced viral replication precedes overt hepatitis. J Med Virol 65:473-477, 2001
39. Khaled Y, Hanbali A: Hepatitis B virus reactivation in a case of Waldenstrom's macroglobulinemia treated with chemotherapy and rituximab despite adefovir prophylaxis. Am J Hematol 82:688, 2007